Back to top
more

Zymeworks (ZYME)

(Real Time Quote from BATS)

$10.55 USD

10.55
37,399

+0.15 (1.44%)

Updated Jul 25, 2024 10:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zymeworks Inc. (ZYME) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Zymeworks Inc. (ZYME) closed at $8.22, marking a -1.91% move from the previous day.

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of 0.96% and 1.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Flat As Market Sinks: What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) closed the most recent trading day at $8.57, making no change from the previous trading session.

Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks Inc. (ZYME) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) closed the most recent trading day at $8.90, moving -0.22% from the previous trading session.

Can Zymeworks (ZYME) Beat Expectations This Earnings Season?

by Zacks Equity Research

In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly zanidatamab for the treatment of patients with HER2-expressing cancers, at the fourth-quarter conference call.

Zymeworks Inc. (ZYME) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) closed the most recent trading day at $9.70, moving -1.22% from the previous trading session.

Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zymeworks Inc. (ZYME) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) closed at $9.45 in the latest trading session, marking a -0.94% move from the prior day.

Zymeworks Inc. (ZYME) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) closed the most recent trading day at $9.78, moving -0.41% from the previous trading session.

Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival

by Zacks Equity Research

Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.

How Much Upside is Left in Zymeworks Inc. (ZYME)? Wall Street Analysts Think 65.75%

by Zacks Equity Research

The mean of analysts' price targets for Zymeworks Inc. (ZYME) points to a 65.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why

by Zacks Equity Research

Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.

Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.

Sundeep Ganoria headshot

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

by Sundeep Ganoria

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

Zymeworks Inc. (ZYME) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug

by Zacks Equity Research

Following positive data from a mid-stage study evaluating Zymeworks' (ZYME) lead candidate, Jazz (JAZZ) exercises its option to acquire the rights to develop and market this candidate.

Why Zymeworks Inc. (ZYME) Might be Well Poised for a Surge

by Zacks Equity Research

Zymeworks Inc. (ZYME) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Wall Street Analysts Believe Zymeworks Inc. (ZYME) Could Rally 59%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 58.7% upside potential for Zymeworks Inc. (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option

by Zacks Equity Research

Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.

Zymeworks Inc. (ZYME) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 23.40% and 44.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals

by Zacks Equity Research

Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.